Browse the evidence

Tirzepatide is preferred over semaglutide due to less reported side effects and enhanced benefits in promoting bone formation.

Tirzepatide may be a better option for patients needing obesity management with fewer side effects.

Obesity is associated with increased risk of cancer, accounting for approximately 10% of new cancer diagnoses annually in the US.

Healthcare practitioners should consider obesity as a significant risk factor for cancer in their patients.

Adverse events from semaglutide were generally mild to moderate gastrointestinal effects and occurred more frequently in the semaglutide group.

Clinicians should monitor for mild to moderate gastrointestinal side effects in patients treated with semaglutide.

Semaglutide (SEM) and tirzepatide (TIR) use was associated with greater annualized total hip (TH) bone loss in patients without diabetes mellitus (DM) compared to controls.

Practitioners should monitor bone health in patients using GLP-1 RAs, especially those without DM.

Total hip (TH) bone loss was comparable between GLP-1 RA users and controls among patients with diabetes mellitus (DM).

Bone health monitoring may be less critical for patients with DM using GLP-1 RAs.

Atherogenic dyslipidemias are a major contributor to ASCVD within the CKM framework.

Recognize and address dyslipidemias in patients with obesity to mitigate cardiovascular disease risk.

GLP-1 RA users had a higher incidence of delayed wound healing (18.5% versus 7.5%) compared to nonusers.

Practitioners should monitor GLP-1 RA users for delayed wound healing post-surgery.

GLP-1 RA users had lower seroma rates (4.9% versus 14.0%) compared to nonusers.

Practitioners may consider GLP-1 RAs for potentially reducing seroma formation post-surgery.

Over half of patients with type 2 diabetes fail to meet glycemic targets due to clinical inertia.

Practitioners should be aware of the impact of clinical inertia on treatment outcomes.

Microneedle (MN)-based technologies provide a painless drug delivery approach that targets adipose tissue directly, minimizing systemic exposure and reducing the required dosage.

Practitioners may consider MNs as a viable alternative for delivering anti-obesity medications effectively.

Powerlifters exhibited significantly less shoulder extension and horizontal abduction, and hip flexion, extension, and adduction than recreationally strength-trained men.

Powerlifters may need to address limitations in shoulder and hip ROM to optimize performance.

The goal of management in T2D patients with significant fibrosis is to slow the progression of liver disease and reduce associated clinical events.

Clinicians should aim to adapt therapies to manage liver disease progression in diabetic patients.

Significant weight loss can lead to aesthetic challenges such as skin laxity.

Practitioners should be aware of potential aesthetic issues in patients after significant weight loss.

Adverse side effects from GLP-1 receptor agonists are mostly gastrointestinal but may also include loss of muscle and bone mass.

Monitor for gastrointestinal side effects and potential muscle and bone mass loss in patients using GLP-1 receptor agonists.

Performing additional sets of resistance exercise does not inherently result in greater increases in muscle size compared to lower volumes.

Practitioners should not assume that increasing the number of sets will always lead to greater muscle growth.

DXA-derived lean mass, BIA-derived skeletal muscle mass, and BodPod-derived fat-free mass overestimate D3-Cr-derived skeletal muscle mass.

Practitioners should be cautious of overestimations when using these common body composition assessment methods.

DXA, BIA, and ultrasound-derived appendicular lean mass uniformly underestimate D3-Cr-derived skeletal muscle mass by approximately 2.50 kg.

Practitioners should consider the potential underestimation when using these methods for assessing appendicular lean mass.

There are trivial hypertrophic effects between proximal, mid-belly, and distal muscle sites.

Trivial differences in hypertrophy suggest that exercise selection may not need to prioritize specific muscle lengths.

The 'Competition Model of Metabolism' explains stability of physiological states despite metabolic perturbations.

Recognizing the mechanisms behind stability can inform interventions for weight management.

GLP-1 receptor agonists may modify aortic disorders through anti-inflammatory, antioxidant, and antiatherogenic properties.

GLP-1 RAs could be considered for patients with aortic disorders due to their beneficial properties.

Early identification of physical frailty in the liver transplantation clinical pathway is essential for targeted interventions.

Clinicians should implement screening tools for frailty in liver transplant candidates to tailor interventions.

All active treatments, including Dapagliflozin 10 mg, Survodutide, Tirzepatide, and higher-dose Semaglutide, improved fibrosis versus placebo.

Practitioners can consider these anti-diabetic agents as effective options for improving liver fibrosis in patients with MASH.

Dose-dependent effects were more prominent for MASH resolution than fibrosis improvement.

Practitioners should consider the dosage of anti-diabetic agents when aiming for MASH resolution.

GLP-1 agonists influence various obesity-related processes including food intake regulation, insulin resistance, and inflammation.

Understanding these mechanisms can help practitioners tailor obesity treatments more effectively.